OILVEQ:意大利大麻油制剂中 cannabinoids 分析的外部质量评估方案
意大利国家卫生研究院于2019年起开展两轮大麻油制剂中THC、CBD、THCA-A和CBDA测定的质量评估,涉及十六家意大利实验室。第一轮仅28.6%实验室Z-score在±2内且均用LC-MS,第二轮无实验室达标,提示需标准化方法并参与质控方案。
要点
- 两轮质控中满意结果普遍偏低(0.0-75.0%),仅样品22-1B的THCA-A测定达100%。
- 第一轮仅28.6%实验室Z-score±2内且均用LC-MS,第二轮无实验室达标。
- GC-MS测定两轮平均ERR%约42%、平均CV%约70%;LC-MS平均ERR%约36%、平均CV%约33%。
核心结论
- 结果强调所有计划将油性大麻制品滴定纳入常规分析的实验室需采用清晰一致的方案。
- 方法标准化和参与质控方案对确保可靠准确的测量至关重要。
研究设计与样本
- 意大利国家卫生研究院设立的质量控制项目,2019年起开展两轮练习,涉及十六家意大利实验室。
- 每轮发送1 mL大麻油样品:第一轮为19-1A和19-1B,第二轮为22-1A、22-1B和22-1C。
- 通过计算Z-score评估各实验室定量性能。
主要发现
- 第一轮十四家实验室中八家用LC-MS、六家用GC-MS;第二轮十一家中六家用GC-MS、五家用LC-MS。
- 第一轮仅28.6%实验室Z-score在±2内且均用LC-MS,第二轮无实验室达标。
- 基于Z-score的满意结果普遍偏低(0.0-75.0%),仅样品22-1B的THCA-A测定为100%。
- 第二轮报告三例假阴性(两例THC和一例CBD,均为GC-MS测定),空白样品无假阳性。
- GC-MS两轮平均ERR%约42%、平均CV%约70%;LC-MS平均ERR%约36%、平均CV%约33%。
临床怎么用
- 实验室应将大麻油制品滴定纳入常规分析时采用清晰一致的标准化方案。
- 参与外部质量评估方案以提升医学大麻治疗测量的可靠性和准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Italy legalized cannabis oil for specific medical conditions (neuropathic pain, refractory epilepsy and other established pathologies) in 2015, but mandates titration of principal cannabinoids before marketing each batch using iphenated techniques coupled with mass spectrometry. To assess reliability of laboratories from the Italian National Health Service in charge of titrating the batches, the Italian National Institute of Health set up an quality control program on determination of Δ9-tetrahydrocannabinol l (THC), cannabidiol (CBD), Δ9-tetrahydrocannabinolic acid A (THCA-A) and cannabidiolic acid (CBDA) in cannabis oil preparations. METHODS: Two rounds of exercises have been carried out since 2019, involving sixteen Italian laboratories. Five different cannabis oil samples (19-1A and 19-1B for the first round and 22-1A, 22-1B and 22-1C for the second one were prepared and 1 mL amount of each sample was sent to the laboratories. The quantitative performance of each laboratory was assessed calculating the Z-score value, a statistical measurement for value's relationship to the mean of a group of values. RESULTS: In the first round, eight out of fourteen laboratories employed an LC-MS while the remaining six used GC-MS. Differently, in the second round, six out of eleven laboratories employed a GC-MS while the remaining five used LC-MS. In the first round, only 28.6 % laboratories achieved an acceptable performance (Z-score±2), and all of them used LC-MS as analytical method. In the second round, none of the laboratories achieved an acceptable performance. Satisfactory results, based on Z-scores, were generally low (0.0-75.0 %), with only one exception of 100 % for THCA-A determination in sample 22-1B. In the second round, three false negatives (two THC and one CBD by GC-MS determination) were reported while no false positives were described in the blank sample. The two rounds yielded a mean ERR% of 42 % approximately and a mean CV% around 70 % in GC-MS determination. When applying LC-MS determination, the two rounds yielded a mean ERR% of 36 % approximately and a mean CV% around 33 %. CONCLUSIONS: The obtained results underline the need for a clear and consistent protocol to be adopted by all laboratories intending to include the titration of oily cannabis-based products into their routinely analytical techniques. This emphasis on methodology standardization and participation to quality control schemes is essential for ensuring reliable and accurate measurements, ultimately enhancing the overall effectiveness and reliability of medical cannabis treatments.
引用
- Rotolo MC, Graziano S, Minutillo A, et al. OILVEQ: an Italian external quality control scheme for cannabinoids analysis in galenic preparations of cannabis oil. Clin Chem Lab Med. 2024. PMID: 38727000. doi:10.1515/cclm-2024-0311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。